# The Chrono

The Chrono-Metabolic Uncoupling Model of Schizophrenia: A Unified Mechanistic Framework Linking Inhibitory Circuit Failure, Oxidative Stress, and Tumor Suppression

Abstract 

Objective: The dopamine hypothesis has long dominated schizophrenia research, yet it fails to explain the disorder's negative symptoms, oscillatory nature, or inverse comorbidity with cancer. This narrative review proposes the "Chrono-Metabolic Uncoupling Model," a unified framework integrating neurophysiology, bioenergetics, and oncology to reframe schizophrenia as a failure of inhibitory gating driven by systemic metabolic lesions.

Methods: We synthesized literature from 1990 to 2024 across three distinct domains: parvalbumin (PV+) interneuron bioenergetics, redox-dependent epigenetics, and the p53/tumor-suppressor axis. We prioritized mechanistic studies that provided cross-disciplinary links between mitochondrial dysfunction and neural circuit failure.

Results: The synthesis reveals that PV+ interneurons, which generate the gamma oscillations required for cognitive binding, operate at a thermodynamic limit that makes them uniquely vulnerable to oxidative stress. In schizophrenia, a systemic "Warburg-like" metabolic shift and glutathione deficit cause these neurons to fail. This failure is reinforced by a "Life History Trade-off": the schizophrenic genome exhibits hyperactivity in the p53 tumor-suppressor pathway, which protects against cancer but drives post-mitotic neurons into a state of "senescent stagnation," preventing synaptic plasticity.

Conclusion: Schizophrenia functions as a "metabolic lockout" where the brain sacrifices complex timing circuits to ensure cellular survival. We propose the "Chrono-Metabolic Protocol"—a therapeutic strategy combining redox support (NAC), epigenetic unlocking (SAMe/P5P), and adrenergic resynchronization (Guanfacine)—to restore the metabolic reserve and firing fidelity of the inhibitory control system.



1. Introduction: Reframing the Central Problem

1.1 The Inadequacy of the Dopamine Hypothesis

For over five decades, the dopamine hypothesis has dominated schizophrenia research, proposing that the disorder results from excessive striatal dopamine signaling (1). While dopamine D2-receptor antagonists effectively reduce positive symptoms (hallucinations, delusions, agitation), this framework fails to address three critical clinical realities (1).

First, it offers no mechanistic explanation for negative symptoms—the profound apathy, anhedonia, and cognitive withdrawal that often precede psychosis and persist after positive symptoms resolve (1). These symptoms suggest reduced, not elevated, dopaminergic function. Second, dopamine antagonists frequently worsen negative symptoms, creating a therapeutic paradox where treating psychosis deepens functional impairment (2). Third, the model cannot explain the oscillatory nature of schizophrenia: patients cycle between hyperaroused, disorganized states (positive symptoms resembling mania) and hypoaroused, withdrawn states (negative symptoms resembling depression) (2). If schizophrenia were purely a "high dopamine" state, the metabolic collapse of the negative phase would be inexplicable (2).

These failures suggest that elevated dopamine is a downstream compensatory response, not a primary lesion. I propose that schizophrenia represents a failure of inhibitory gating—a collapse of GABAergic and adrenergic mechanisms enabling transitions between high-gain (arousal/focus) and low-gain (rest/safety) neural states. This shifts the conceptual model from a "broken part" to a "broken oscillator."

1.2 Historical and Biological Context

This oscillatory perspective is not new but forgotten. Kraepelin acknowledged "agitated and circular" forms of Dementia Praecox characterized by rapid fluctuations between grandiosity and stupor (3, 4). Modern genome-wide association studies reveal significant genetic overlap between schizophrenia and bipolar disorder, particularly in genes regulating calcium channels and synaptic plasticity (5). The National Institute of Mental Health's Research Domain Criteria initiative explicitly favors circuit-based domains over categorical diagnoses (6), supporting my reconceptualization of schizophrenia's "anger/psychosis" and "depression/negative" states as opposing poles of a single dysregulated timing circuit.

1.3 A Mechanistic Synthesis

Understanding this oscillatory failure requires examining mechanisms spanning multiple biological scales—from mitochondrial bioenergetics to systemic tumor suppressor pathways. This article integrates findings from neurophysiology (parvalbumin interneuron bioenergetics), epigenetics (redox-dependent DNA methylation), and oncology (inverse comorbidity with cancer) to propose the Chrono-Metabolic Uncoupling Model. I argue that the schizophrenic brain is trapped in "senescent stagnation"—neurons too metabolically stressed to function (causing GABAergic deficits) but genetically prevented from dying (due to hyperactive p53). This trade-off explains why genetic factors protecting against cancer predispose to synaptic failure.



2. Methods

This article presents a narrative review synthesizing findings across neurophysiology, bioenergetics, and oncology to construct a unified mechanistic framework for schizophrenia.

2.1. Search Strategy
We conducted a targeted literature search using PubMed, Google Scholar, and Scopus for articles published from January 1990 to December 2024. The search strategy prioritized mechanistic links between distinct biological domains. Key search terms included combinations of: "Parvalbumin interneurons," "Perineuronal nets," "Schizophrenia bioenergetics," "Glutathione deficit," "p53 and Schizophrenia," "Inverse cancer comorbidity," and "Wnt signaling in psychosis."

2.2. Selection Criteria and Synthesis
Articles were selected based on their relevance to three specific thematic intersections: (1) The metabolic vulnerability of fast-spiking interneurons; (2) The relationship between oxidative stress and epigenetic remodeling; and (3) The systemic trade-off between tumor suppression (p53) and synaptic plasticity. While this is not a systematic review, I prioritized meta-analyses, Genome-Wide Association Studies (GWAS), and highly cited mechanistic studies to ensure the reliability of the foundational data. The synthesis focuses on integrating these disparate findings into the "Chrono-Metabolic Uncoupling" model proposed herein.



3. The Neural Circuit Architecture of Oscillatory Failure

3.1 Parvalbumin Interneurons: The Cortical Metronome

Conscious perception requires temporal integration: the brain must bind fragmented sensory inputs into a unified "now." This binding occurs through gamma-band oscillations (30-80 Hz), high-frequency rhythms synchronizing neuronal firing across cortical regions (7). The cellular generators are fast-spiking parvalbumin-positive (PV+) interneurons, GABAergic cells functioning as the cortical metronome (7). By firing with millisecond precision, PV+ interneurons provide rhythmic inhibition to pyramidal neurons, creating temporal windows for organized firing and enabling the brain to distinguish signal from noise (7).

However, this precision demands extraordinary metabolic investment. To sustain firing rates exceeding 100 Hz, PV+ interneurons utilize specialized Kv3.1 potassium channels enabling ultra-rapid membrane repolarization (8). Each firing cycle requires massive ion flux, and restoring electrochemical gradients demands continuous ATP generation by Na+/K+-ATPase pumps (8). Consequently, PV+ interneurons contain exceptionally high mitochondrial and cytochrome c oxidase densities—they are metabolic "Formula 1 engines" delivering exceptional performance but requiring continuous fuel (8).

This creates specific vulnerability: operating near thermodynamic limits, PV+ neurons are exquisitely sensitive to mitochondrial dysfunction (8). In schizophrenia, mitochondrial complex I deficits compromise ATP generation (8). When energy supply cannot meet demand, PV+ neurons fail catastrophically (9). The result is gamma desynchronization—the metronome stops, and temporal binding collapses (9). Phenomenologically, this manifests as fragmented perception, inability to distinguish internal thought from external voice, and loss of cognitive coherence—the core positive symptoms (9). Critically, PV+ neurons are present but functionally impaired, suggesting potential reversibility (9).

3.2 Perineuronal Nets: The Melting Shield

To protect these stressed neurons, the brain evolved perineuronal nets (PNNs)—lattice-like matrices of chondroitin sulfate proteoglycans ensheating PV+ interneurons (10). PNNs serve two critical functions: negatively charged sulfate groups act as cation buffers facilitating rapid ion exchange for fast spiking, while the physical structure acts as a redox shield blocking reactive oxygen species (ROS) from damaging membranes (10).

In schizophrenia, post-mortem studies reveal dramatic PNN reductions in prefrontal cortex without substantial neuronal death—neurons are "naked," stripped of protection (10). This degradation is enzymatically driven by matrix metalloproteinase-9 (MMP-9), released by stressed astrocytes and microglia, which digests PNN proteoglycans (11). The sequence: oxidative stress activates glia → MMP-9 release → PNN degradation → unprotected neurons become hypersensitive to ROS → oxidation of Kv3.1 channels → gamma collapse (11). This explains schizophrenia as a "connectivity disorder" despite minimal cell loss: the hardware remains, but the cooling system has melted (11).

3.3 The Adrenergic Toggle Switch

While PV+ interneurons generate cortical rhythms, the locus coeruleus controls gain via norepinephrine (NE), operating through anatomically segregated receptor systems functioning as a physiological toggle switch (12, 13, 14).

The Prefrontal Brake: In dorsolateral prefrontal cortex, alpha-2A adrenergic receptors on pyramidal neuron dendritic spines inhibit adenylyl cyclase, reducing cyclic AMP (cAMP) and closing hyperpolarization-activated cyclic nucleotide-gated (HCN) channels (12). This increases membrane resistance, preventing signal leakage and enabling "rational control"—sustained attention and top-down inhibition (12). However, during acute stress when NE surges, excess NE activates alpha-1 and beta receptors, which increase cAMP, open HCN channels, and cause signal leakage—"prefrontal shutdown" (13).

The Striatal Accelerator: Simultaneously, elevated NE activates alpha-2C receptors in striatum and basal ganglia, facilitating dopamine release and the "fight-or-flight" response (14). When prefrontal alpha-2A collapses and striatal alpha-2C increases, the organism enters "limbic release"—the rational brake fails, and instinctual drive dominates (13, 14). This is the physiological substrate of "anger/psychosis." 



3.4. A Theoretical Derivation of Symptom Periodicity

While clinical observation confirms that many patients fluctuate between agitation and withdrawal, the specific circadian timing of these shifts has not been definitively mapped in the literature. However, by synthesizing the established bioenergetics of the PV+ neuron with known circadian physiology, we can derive a logical mechanism for this oscillation.

Step 1: The Metabolic Constraint. As established, the PV+ interneuron operates at the thermodynamic limit of its mitochondrial capacity (8). It has little "reserve fuel."
Step 2: The Circadian Load. Human physiology dictates a sharp rise in Cortisol and Norepinephrine (NE) immediately upon awakening (the Cortisol Awakening Response).
Step 3: The Receptor Vulnerability. High levels of NE drive the prefrontal cortex from a state of "Alpha-2A dominance" (Focused) to "Alpha-1 dominance" (Disorganized) (13).

The Logical Synthesis: In a healthy brain, the metabolic reserve is sufficient to buffer this morning surge, maintaining inhibition. In the schizophrenic brain, I hypothesize that the morning neurochemical surge places a maximal demand on the "Formula 1" PV+ neurons exactly when their PNN shielding is weakest. This would logically precipitate a "Threshold Failure"—a collapse of inhibitory gating that manifests as the hyper-aroused, disorganized state of Psychosis.

Conversely, as the day progresses, the continuous metabolic cost of maintaining even sub-optimal firing would progressively deplete the neuron's ATP and Glutathione reservoirs. By evening, the system would logically enter a state of "Metabolic Exhaustion"—a forced shutdown of firing to prevent cell death. This bioenergetic collapse would manifest clinically not as active psychosis, but as the avolition, stupor, and withdrawal characteristic of the Negative Phase. Thus, I propose that the "Mixed State" of schizophrenia is actually a "Metabolic Sine Wave" driven by the mismatch between circadian demand and mitochondrial supply.





4. The Metabolic Origins: From Oxidative Stress to Epigenetic Silencing

4.1 The Glutathione Deficit

The metabolic vulnerability of PV+ interneurons reflects an intrinsic antioxidant deficit. Most neurons synthesize glutathione (GSH)—the brain's primary antioxidant—from cysteine precursors (16). However, PV+ interneurons operating at extreme metabolic rates have outsourced antioxidant defense to neighboring astrocytes (16). Astrocytes normally synthesize GSH and export precursors for neuronal uptake—the "astrocyte-to-neuron shuttle" (16).

In schizophrenia, this partnership is broken. Genetic polymorphisms in GCLC (the rate-limiting GSH synthesis enzyme) reduce astrocytic GSH production (17). When astrocytes cannot meet Formula 1 PV+ neuron demands, neuronal ROS levels skyrocket (17). This unchecked oxidative stress causes immediate physical damage (membrane oxidation, PNN degradation) and activates stress-response signaling cascades triggering epigenetic adaptations (11, 17). The "anger" phase corresponds to high ROS/low GSH—the engine redlining, structures melting. This sets the stage for epigenetic silencing characterizing the "depression" phase.

4.2 DNA Methylation as Metabolic Hibernation

For decades, downregulation of GAD67 (the GABA synthesis enzyme) and Reelin was interpreted as fixed genetic damage (15). However, reversibility in animal models suggests epigenetic silencing as metabolic adaptation rather than genetic destruction (15).

The key enzyme is DNA methyltransferase 1 (DNMT1), which methylates cytosine residues in gene promoters, reducing transcription (15). In schizophrenic prefrontal cortex, DNMT1 is consistently upregulated (15). The mechanistic link: ROS activates protein kinase C and NF-κB pathways, increasing DNMT1 transcription (15). Upregulated DNMT1 methylates CpG-rich promoters, notably GAD67 and RELN (15).

Why silence inhibitory machinery under stress? The answer is bioenergetics. Synthesizing and releasing GABA at high frequencies requires continuous glutamate uptake, enzymatic conversion, vesicular packaging, and exocytosis—all ATP-dependent (15). By methylating the GAD67 promoter, the cell "turns off the factory," reducing metabolic overhead (15). This is not pathology but a survival strategy—the neuron chooses reduced function (metabolic hibernation) over excitotoxic death (15). The tragedy: this temporary adaptation becomes a chronic "epigenetic trap" (15). Even when oxidative stress subsides, methylation marks persist, keeping neurons silenced (15).

4.3 The One-Carbon Cycle: The Folate Trap

Epigenetic states depend on the one-carbon cycle, generating methyl groups for DNA methylation and sulfur amino acids for glutathione synthesis (18). Homocysteine sits at a metabolic crossroads with two competing pathways (18):

Methylation pathway: Homocysteine → methionine → S-adenosylmethionine (SAMe, the universal methyl donor)

Transsulfuration pathway: Homocysteine → cysteine → glutathione

In chronic oxidative stress, the cell faces a "devil's bargain": desperate for glutathione, it shunts flux toward transsulfuration, depleting the homocysteine pool for SAMe generation (18). The result: global DNA hypomethylation (genomic instability) coexisting with focal hypermethylation of stress genes like GAD67 (driven by upregulated DNMT1 competing for depleted SAMe) (18). The system cannot maintain genomic integrity because resources are diverted to antioxidant defense, yet cannot neutralize oxidative stress because glutathione machinery is overwhelmed (18). This explains elevated homocysteine levels in schizophrenia—a biomarker of this metabolic bottleneck (18).



The Systemic Context: Inverse Comorbidity with Cancer

5.1 Epidemiological Evidence for Biological Trade-Off

If schizophrenia reflects fundamental metabolic alteration, this should leave a systemic fingerprint. That fingerprint exists: the inverse comorbidity between schizophrenia and cancer (19, 20). Despite higher rates of smoking, obesity, and metabolic syndrome, schizophrenia patients exhibit significantly reduced cancer incidence, particularly lung and prostate cancers (19). Conversely, cancer survivors show reduced Alzheimer's risk (20).

This pattern suggests a biological trade-off: cellular machinery tuned toward proliferation/growth (risk: cancer) or arrest/safety (risk: neurodegeneration) (19, 20). Schizophrenia occupies an extreme position—a state of premature cellular senescence where cells refuse to die but refuse to function normally (22).

5.2 The p53 Paradox: Guardian Becomes Jailer

The master regulator is p53, the "guardian of the genome" (21, 22). In cancer, p53 detects DNA damage and forces apoptosis or senescence, preventing tumors (22). Approximately 50% of cancers harbor p53 mutations disabling this brake (22).

In schizophrenia, the opposite pattern emerges: overrepresentation of pro-apoptotic/pro-senescent p53 polymorphisms (such as Arg72Pro) (21). The schizophrenic genome is "trigger-happy," activating cell cycle arrest at minimal provocation (21). This explains low cancer rates: the body efficiently shuts down potential tumors (21).

But in post-mitotic neurons, chronically activated p53 cannot execute apoptosis, so it pushes neurons into cellular senescence—a "zombie state" (22). Neurons remain metabolically active but functionally arrested—withdrawing synapses, halting plasticity protein synthesis, focusing on survival (22).

5.3 A Proposed Mechanistic Loop


The central regulator of this trade-off is the TP53 gene (encoding p53), the "Guardian of the Genome." In cancer, p53 mutation or silencing removes the safety brake, allowing uncontrolled proliferation. In schizophrenia, however, genetic association studies have identified an over-representation of pro-apoptotic/pro-senescent p53 polymorphisms (such as the Arg72Pro variant) in patient cohorts (21). This suggests the schizophrenic genome may be "biased" toward detecting stress and arresting cellular function.

I propose a mechanistic model linking this systemic p53 bias to the specific circuit failures described in Section 2. In this model, chronic oxidative stress in the "Formula 1" PV+ interneurons triggers the hypersensitive p53 system. Instead of apoptosis, p53 activation in post-mitotic neurons or their supporting glia can induce a state of Cellular Senescence (22). Senescent cells acquire a Senescence-Associated Secretory Phenotype (SASP), actively secreting pro-inflammatory cytokines and tissue-remodeling enzymes. Crucially, a primary component of the SASP cocktail is Matrix Metalloproteinase-9 (MMP-9) (22).

This creates a plausible, self-reinforcing loop:

Metabolic Trigger: High firing rates in PV+ neurons deplete Glutathione, causing ROS accumulation (16).

Sensor Activation: ROS activates the p53 signaling pathway (21).

Effector Response: p53 drives local glial or neuronal elements into a senescent, secretory state (22).

Structural Damage: Secreted MMP-9 digests the protective Perineuronal Nets (11).

Functional Collapse: The "naked" PV+ neuron loses its fast-spiking fidelity, leading to Gamma desynchrony (9).

While direct evidence of this full chain in human schizophrenia remains inferential, the individual links—high Oxidative Stress, p53 activation, MMP-9 upregulation, and PNN loss—are all well-documented features of the disorder.

4.4 Wnt Suppression: The "Safety Mode" Hypothesis
This metabolic stagnation appears to be reinforced by a second pathway: Wnt Signaling. Wnt drives neurogenesis and synaptic plasticity, acting as a functional counterweight to p53. In schizophrenia, Wnt signaling is chronically attenuated (23). Low Wnt activity compromises the maintenance of dendritic spines and the incorporation of AMPA receptors required for learning (23).

The combination of low Wnt (reduced plasticity) and high p53 (enhanced arrest) creates a biological profile that favors somatic preservation over neural flexibility. Epidemiological data consistently support this "Inverse Comorbidity," showing that schizophrenic patients have a significantly reduced incidence of multiple cancers (19) and that cancer survivors have a lower risk of developing Alzheimer's disease (20). This pattern is consistent with the hypothesis that schizophrenia represents a Life History Trade-off—a systemic shift where the organism’s cellular machinery is tuned so aggressively against uncontrolled growth (Cancer) that it inadvertently stifles the structural plasticity required for complex cognition.



5. Discussion: The Chrono-Metabolic Protocol
The "Chrono-Metabolic Uncoupling" framework suggests that current pharmacological standards, primarily D2-receptor antagonists, address the downstream symptom (psychosis) but leave the upstream metabolic and epigenetic lesions untreated. To move from palliation to resynchronization, I propose a theoretical therapeutic framework—the Chrono-Metabolic Protocol—that targets the three distinct layers of the failure identified in this review.

5.1 Phase I: The Epigenetic Unlock (Redox-Methylation Reset)
The first target is the epigenetic silencing of GAD67 and RELN. Clinical trials have explored N-Acetyl Cysteine (NAC) as an adjunct therapy, with meta-analyses showing moderate efficacy in reducing negative symptoms (24). Mechanistically, NAC replenishes the glutathione reservoir that PV+ neurons cannot maintain themselves, reducing the oxidative drive for DNMT1 upregulation (16).

However, my model suggests that antioxidant support alone may be insufficient to reverse established methylation marks. I hypothesize that combining NAC with S-Adenosylmethionine (SAMe) could offer a synergistic benefit. While SAMe provides the methyl groups necessary to restore genomic stability, its use in schizophrenia has been controversial due to the risk of exacerbating agitation (18). I propose that this risk stems from the "Folate Trap": without adequate antioxidant coverage (NAC), SAMe is diverted to the transsulfuration pathway. A combined approach—using NAC to satisfy the antioxidant demand and SAMe to drive epigenetic re-regulation—warrants controlled clinical investigation.

5.2 Phase II: The Enzymatic Refuel (The B6 Cofactor)
Even with accessible gene promoters, GABA synthesis requires the cofactor Pyridoxal-5-Phosphate (P5P). The conversion of dietary Vitamin B6 to P5P is compromised by chronic inflammation, a common feature of schizophrenia (2). This creates a "functional deficiency" where peripheral B6 levels may be normal, but central P5P availability is low. Direct supplementation with bio-active P5P, rather than generic Pyridoxine, theoretically bypasses this inflammatory block to restore GAD67 enzymatic function, though specific trials comparing B6 forms in schizophrenia are currently lacking.

5.3 Phase III: Adrenergic Resynchronization (The Noise Filter)
Finally, to restore the "gating" of the resupplied GABA, we look to the Alpha-2A adrenergic receptor. In the Prefrontal Cortex, Alpha-2A stimulation inhibits cAMP-HCN channel signaling, effectively "closing the leak" in dendritic spines (12). Guanfacine, a selective Alpha-2A agonist, is currently used in ADHD to improve working memory. Given the shared deficits in prefrontal gating, Guanfacine represents a logical candidate for "Circuit Resynchronization" in schizophrenia. Integrating Sarcosine to stimulate the NMDA glycine site may further boost the excitatory drive required to restart the PV+ Gamma metronome (27).

6. Conclusion
Schizophrenia is not a random collection of symptoms; it is a coherent failure of the brain's timing and energy infrastructure. By integrating the "Hardware" (PV+ neurons), the "Software" (Epigenetics), and the "Systemic Context" (Cancer/p53), we can see beyond the dopamine hypothesis. The Parvalbumin neuron is not dead; it is in a state of metabolic hibernation. The challenge for future research is to prove that with the right combination of redox, epigenetic, and adrenergic support, it can be woken up.

Conflict of Interest Statement

The authors declare no conflicts of interest.

Funding Statement

This research received no specific grant from any funding agency

Ethical approval: This article is a narrative review and does not involve any new studies with human participants or animals performed by the authors.



References

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35(3):549-562.

Torrey EF, Davis JM. Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas. Wiley-Blackwell; 2012.

Kraepelin E. Psychiatrie. Ein Lehrbuch für Studirende und Aerzte. 6th ed. Barth; 1899.

Kendler KS, Jablensky A. Kraepelin's concept of the circular forms of dementia praecox. Am J Psychiatry. 2010;167(8):889.

Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381(9875):1371-1379.

Insel TR, Cuthbert B, Garvey M, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748-751.

Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11(2):100-113.

Kann O, Papageorgiou IE, Draguhn A. Highly energized inhibitory interneurons are a central element for information processing in cortical networks. J Cereb Blood Flow Metab. 2014;34(8):1270-1282.

Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35(1):57-67.

Mauney SA, Athanasiou M, Pantazopoulos H, et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol Psychiatry. 2013;74(6):427-435.

Steullet P, Cabungcal JH, Monin A, et al. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol Psychiatry. 2017;22(7):936-943.

Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397-410.

Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10(6):410-422.

Uys MM, Shahid M, Harvey BH. Therapeutic potential of selectively targeting the α2C-adrenoceptor in the treatment of schizophrenia. Front Neurosci. 2017;11:244.

Gavin DP, Sharma RP. Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev. 2010;34(6):882-888.

Do KQ, Cabungcal JH, Frank A, et al. Schizophrenia: glutathione deficit in parvalbumin interneurons. Curr Opin Neurobiol. 2009;19(3):220-230.

Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A. 2007;104(42):16621-16626.

Krebs MO, Bellon A, Mainguy G, et al. One-carbon metabolism and schizophrenia: current challenges and future directions. Mol Psychiatry. 2009;14(6):575-585.

Catts VS, Catts SV, O'Toole BI, et al. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr Scand. 2008;117(5):323-336.

Driver JA, Beiser A, Au R, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.

Ni X, Trakalo J, Kennedy JL. Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control study and TDT. Neurosci Lett. 2005;388(3):173-178.

Mijit M, Caracciolo V, Melillo A, et al. Role of p53 in the regulation of cellular senescence. Biomolecules. 2020;10(3):420.

Okerlund ND, Cheyette BN. Synaptic Wnt signaling—a contributor to major psychiatric disorders? J Neurodev Disord. 2011;3(2):162-174.

Ghaderi A, Bussu A, Tsang C, Jafanejad S. Effect of N-Acetylcysteine on Positive and Negative Syndrome Scale associated with Schizophrenia: A Meta-Analysis. Rev Clin Med. 2020;7(3):134-144.

25. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196-1204.



